Alembic Pharma gets approval for moxifloxacin ophthalmic solution

Alembic Pharmaceuticals announced that it received USFDA approval for Moxifloxacin Ophthalmic Solution one of its Abbreviated New Drug Application (ANDA). With this, the total approval count for the company is at 86 approvals. 
  
The company India received the approval for Moxifloxacin Ophthalmic Solution USP, 0.5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Vigamox Ophthalmic solution USP, 0.5% of Novartis Pharmaceuticals corporation. Moxifloxacin ophthalmic solution USP, 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms. Moxifloxacin ophthalmic solution USP, 0.5% has estimated market size of US$ 68 million for the calendar year 2018. 
  
Alembic Pharma’s total ANDA approvals has reached up to 86 approvals. Out of which 73 are final approvals while rest are tentative approvals from US Food and drug administration (USFDA). 
  
On Friday, Alembic Pharma’s stock closed at per share price of Rs. 541.00 with marginal gains of 1.09 per cent on BSE. At the same time, benchmark index BSE Sensex traded with losses of 67.27 points at 35,808.95.